What are the key financial results for FY26?

Mahamaya Lifesciences reported revenue of **₹328.87 crore**, a **24.5%** increase, and a net profit of **₹16.72 crore**, up **30.4%**.

Did the auditor raise any concerns?

No. The board received an unmodified audit opinion on both the standalone and consolidated financial statements.

Does this filing contain new market-moving information?

No. The filing is a routine compliance step that confirms financial figures already disclosed to the market.

Earnings · Pharmaceuticals

Mahamaya Lifesciences confirms FY26 results with no surprises

The company filed its audited standalone and consolidated results for the year ended March 31, 2026, confirming previously disclosed figures.

— 1 earlier story on Mahamaya Lifesciences Ltd. →

MAHALIFE BSE 544611 25 May 2026 · 1:57 PM IST Verify on BSE · NSE

Mkt cap₹390 cr

P/E30.20×

ROE26.19%

Debt / eq.1.18

₹328.87 cr Full-year revenue for FY26, representing a 24.5% increase.

What's new

Mahamaya Lifesciences finalized its audited FY26 financial results.
The board received an unmodified audit opinion on the accounts.
The filing confirms previously announced revenue and profit figures.

Why this matters

This is a routine compliance filing that adds no new information to the market. The company has formalized the financial data it already released.

What we're watching

Future updates on the utilization of IPO proceeds.
Management commentary on sustaining the 30.4% profit growth.
Upcoming quarterly disclosures for FY27.

The full read

Mahamaya Lifesciences has completed its formal reporting process for the year ended March 31, 2026.

It is a routine update.

The board approved the audited standalone and consolidated results, which confirm the previously announced revenue of ₹328.87 crore and net profit of ₹16.72 crore, representing year-on-year growth of 24.5% and 30.4% respectively. Because the data was already public, this release is a regulatory requirement rather than a source of new information for investors, and the inclusion of an unmodified audit opinion and details regarding the utilization of IPO proceeds simply closes the books on the fiscal year.

Questions answered

What are the key financial results for FY26?: Mahamaya Lifesciences reported revenue of ₹328.87 crore, a 24.5% increase, and a net profit of ₹16.72 crore, up 30.4%.
Did the auditor raise any concerns?: No. The board received an unmodified audit opinion on both the standalone and consolidated financial statements.
Does this filing contain new market-moving information?: No. The filing is a routine compliance step that confirms financial figures already disclosed to the market.

Mentioned: Mahamaya Lifesciences Ltd.

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on MAHALIFE →

Today · 1:57 PM IST Mahamaya Lifesciences confirms FY26 results with no surprises
today Mahamaya Lifesciences posts ₹16.72 cr profit in first annual report